Covidien closes enrollment in a pair of clinical trials, Visibility and Durability, examining its iliac stents for treating peripheral artery disease.
Covidien (NYSE:COV) said it closed enrollment in a pair of its Visibility and Durability iliac stent clinical studies.
The prospective, multinational studies are designed to compare balloon stents with self-expanding stents in the iliac arteries for treating peripheral artery disease.
Half of the 150 patients will be treated with the balloon stent and the 2nd cohort with the self-expanding stents at 23 medical centers in the U.S. and Europe. Patients will be evaluated for 9 months, with a 3-year follow-up.
